NECTIN4
Nectin-4
As of the edition of 20 October 2026, NECTIN4 (nectin-4, UniProt Q96NY8) has 7 drugs tested at it and 6 companies on the list, 0 on route A and 1 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q96NY8
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 5
- Disease areas
- Cancer; Urinary and reproductive; Pregnancy and women's health; Skin and connective tissue; Digestive system; Hormones; Lungs and airways; Mouth and teeth
- Registered trials of its drugs
- 90
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 2 |
| Active | 4 |
| Stopped | 1 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Enfortumab vedotin | Marketed | Phase 4 | Ends 2031 |
| SYS6002 | Active | Phase 3 | none listed |
| BT7480 | Active | Phase 2 | none listed |
| CRB-701 | Active | Phase 3 | none listed |
| Enfortumab | Marketed | Phase 1 | none listed |
| SBT6290 | Stopped | Phase 2 | none listed |
| VBC103 | Active | Phase 2 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 1 |
| Engaged | 4 |
| Undetermined | 1 |
| Total on the list | 6 |
| Company | Route |
|---|---|
| Pfizer | Route B |
The other 5 companies at NECTIN4
In the product6 companies in all; 5 are not named here, and no score is.
See the 6 companies at NECTIN4, ranked, with the facts behind eachRequest access. Nothing is shown until you do.